Sangamo Therapeutics shares lost more than half their value when Pfizer pulled out of a collaboration agreement.

Analyst Yanan Zhu of Wells Fargo maintained a Hold rating on Sangamo Biosciences (SGMO – Research Report), retaining the price target of ...

NEW YORK, NY / ACCESSWIRE / January 14, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Sangamo ...

Sangamo faces steep drop after Pfizer ends partnership, raising concerns about its hemophilia therapy's future ...

During post-market hours on December 30, 2024, Sangamo announced that Pfizer, with whom the Company was co-developing hemophilia A gene therapy candidate giroctocogene fitelparvovec, would be ...

Sangamo Therapeutics shares lost more than half their value when Pfizer pulled out of a collaboration agreement. The two drugmakers were working on a treatment for hemophilia in adults.

Unfortunately, Sangamo recently publicized a shocking setback that Pfizer (PFE) has decided to terminate their partnership for their hemophilia A gene therapy program. This announcement has nearly ...

Sangamo intends to explore all options to advance the program, including seeking a potential new collaboration partner. Pfizer has indicated to Sangamo that this termination reflects its decision ...

Dec 30 (Reuters) - Sangamo Therapeutics (SGMO.O), opens new tab said on Monday that partner Pfizer (PFE.N), opens new tab has terminated their hemophilia A gene therapy co-development agreement ...

Pfizer gave Sangamo Therapeutics coal for Christmas, terminating a hemophilia A gene therapy pact to deprive the cash-strapped biotech of up to $220 million in milestones. Pfizer’s decision sent ...